• E-mail :[email]
  • Phone : +33 493377718
  • Location : Nice, France
Last update 2011-03-27 14:02:04.289

Daniel Aberdam PhD Molecular genetics

Course and current status


1980: BA in Biology at the P. & M. Curie University Paris VI

1983: Msc (Neurobiology) at Weizmann Institute of Sciences (Rehovot, Israel)

1990: PhD (Genetics) at Weizmann Institute of Sciences (Rehovot, Israel)

1991-1994 : Postdoctoral  stage (J.P. Ortonne, Nice France)


Previous Employment

1995-2007: Director of Research INSERM (DR2) at INSERM U364 (Nice, France)

2007-        : Director of INSERM U898 (Nice, France)

@font-face { font-family: "Arial"; }p.MsoNormal, li.MsoNormal, div.MsoNormal { margin: 0cm 0cm 0.0001pt; font-size: 12pt; font-family: "Times New Roman"; }p.MsoBodyText, li.MsoBodyText, div.MsoBodyText { margin: 0cm 0cm 0.0001pt; text-align: justify; font-size: 11pt; font-family: "Times New Roman"; }span.CorpsdetexteCar { font-family: Arial; }div.Section1 { page: Section1; }


Fields of expertise: stem cells, development, genetics, epithelial cancers, genotoxic stress.  

Editorial board member of Stem Cells (2009-     )

Editorial board member of Cell Death & Medicine (2010-     )

Editorial board member of Stem Cells and Cloning (2008-     )

Expert for the French Agency of Biomedicine (2006-    )

Expert for the French Parliament on Bioethics  (2004-    )

Member of AFM Scientific Board  (2006-         )

Member of Scientific Board for the Programme National de Recherche en Dermatologie (2006-   )

Member of Interface Committee INSERM-Dermatology (2002-     )

Member of the International Society of Stem Cell Research (2002-    )

Member of the Israeli Stem cell society (2007-    )


Regular referee for:

- submitted manuscripts to: Nature genetics, Embo J, Embo R., Stem cells, CDD, Mol Cell Biol, J Biol Chem, Oncogene, Exp. Dermatol.

- grant applications to:  ACI, ANR, AFM, US-Israel binational grants, NIH, Régions, EEC,...).

Scientific summary

Dr Daniel Aberdam' scientific interests focus on epidermal gene regulation. More recently, his group has focused on the physiopathology of stem cells and designed original cellular models from embryonic stem cells that recapitulate embryonic normal and pathological skin and cornea formation. It allows the characterization of genes and signaling pathways involved in these critical steps, with particular attention on p63 functions and regulation and their involvement in skin defects found in patients affected by human congenital disorders, like ectodermal dysplasia syndromes. This team was the first to demonstrate the ability of pluripotent stem cells to produce a full thickness skin.

Related sites:

Interview by Stem Cells journal:


Presentation of INSERM U898: http://www.youtube.com/watch?v=El_vMPYNl1g



Image d’exemple